- alex
- 25 Jun, 2003
- New York City
As long as only the capital structure is changing, but not the management handling of the business and the relationship with the unions, all the new cash obtained, earned in good times, or secured through guarantees will be still burned out, eventual
- kalina
- 30 Apr, 2003
- New York City
Biotechnology giant Amgen has successfully managed to not only grow stronger during an economic recession but also emerge as a compelling long-term investment choice.
- kalina
- 16 Apr, 2003
- New York City
Pharmaceutical bellwether Eli Lilly faced a considerable drop in revenue after the patent expiry of Prozac, but its healthy pipeline could more than offset this loss.
- vanya
- 07 Apr, 2003
- New York City
Smart investors have realised that even in times of economic and geopolitical uncertainty, some education industry players offer profits and growth that are hard to find elsewhere.
- kalina
- 02 Apr, 2003
- New York City
Even as research efforts of most biotechs are stumbling along without success, Celgene has actually widened its cancer-research program and is fast cruising towards profitability.
- vanya
- 25 Mar, 2003
- New York City
At a time when the war on Iraq is driving stock markets, Weight Watchers is gaining on another one - the war on fat - as Americans spend billions on weight-loss programs & products.
- kalina
- 17 Mar, 2003
- New York City
The growing number of deals in the biotech arena suggests sector consolidation is finally under way. The FDA's recent publication of a key report is also becoming a major catalyst.
- vanya
- 09 Mar, 2003
- New York City
Even though several IT markets are declining, investors can still find growth opportunities in the security sector - particularly, in the firewall/VPN segment.
- kalina
- 03 Mar, 2003
- New York City
The shaky economy has pushed all stocks, including biotechs, to face tough times. Yet, IDEC Pharmaceuticals is one company worth betting on in this highly volatile sector.
- vanya
- 24 Feb, 2003
- New York City
As spam - or unsolicited e-mail - continues to plague corporate networks, the army of vendors offering defences is growing as well. Will fighting spam become big business?
- kalina
- 16 Feb, 2003
- New York City
Despite the many uncertainties associated with the biotech sector, there are several worthy investment choices. Biogen, which got two regulatory approvals lately, is one of them.
- vanya
- 10 Feb, 2003
- New York City
Last year was a sobering one for venture capitalists as investment activity finished at a pace that was the slowest in nearly five years. Will 2003 be better for the VC business?
- kalina
- 03 Feb, 2003
- New York City
Having managed to grow even during an economic slowdown, healthcare and pharma industry top dog Johnson & Johnson, is poised to attain greater heights in the long run.
- vanya
- 27 Jan, 2003
- New York City
Investors have become skittish about software makers, but it might be smart to keep an eye on business intelligence
- kalina
- 20 Jan, 2003
- New York City
The JP Morgan Healthcare meet did little to boost sector stocks, which were already negatively impacted by a slew of bad news. But the market climate is likely to get better soon.